CJC-1295 (No DAC) vs SS-31: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs SS-31

CJC-1295 (No DAC) is a 29-amino acid growth hormone-releasing hormone (GHRH) analog that stimulates pituitary somatotrophs to elevate pulsatile growth hormone (GH) and downstream IGF-1 levels. Conversely, SS-31 (Elamipretide) is a cell-permeable tetrapeptide that selectively targets cardiolipin within the inner mitochondrial membrane, mitigating reactive oxygen species (ROS) and restoring ATP production without activating endocrine receptors.

While both reagents are studied within tissue regeneration and metabolic homeostasis frameworks, their operational mechanisms are entirely non-overlapping. Investigators must select between systemic neuroendocrine axis modulation via CJC-1295 No DAC or direct organelle-level bioenergetic preservation using mitochondriotropic tetrapeptides.

Comparative Specifications Table

To assist laboratory personnel in protocol design, the primary chemical, structural, and operational parameters of CJC-1295 (No DAC) and SS-31 are outlined below:

| Criteria | CJC-1295 (No DAC) | SS-31 (Elamipretide) | | :--- | :--- | :--- | | **Primary Receptor / Target** | GHRH Receptor (GHRHR) | Inner Mitochondrial Membrane / Cardiolipin | | **Mechanistic Class** | GHRH Analog / Secretagogue | Mitochondriotropic Antioxidant / Energetic Restorer | | **Molecular Formula** | C152H252N44O42 | C32H49N9O5 | | **Molecular Weight** | 3367.9 g/mol | 639.8 g/mol | | **Reported Half-Life** | ~30 minutes (rodent plasma) | ~2–4 hours (cellular clearance models) | | **Solubility Profile** | High in aqueous buffers / BAC water | Water-soluble / Saline / BAC water | | **Typical Preclinical Model** | Endocrine signaling, muscle wasting, IGF-1 activation | Ischemia-reperfusion, mitochondrial decay, ROS models | | **Standard Lab Packaging** | 2mg, 5mg lyophilized vials | 10mg, 50mg lyophilized vials |

Researchers seeking to evaluate these profiles against our broader catalog of research peptides can inspect individual product documentation for lot-specific physical data.

Molecular Structure and Pharmacokinetics: CJC-1295 (No DAC)

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic modification of the naturally occurring growth hormone-releasing hormone fragment. The peptide chain contains four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) engineered to enhance resistance against enzymatic degradation by dipeptidyl peptidase IV (DPP-IV).

Unmodified native GHRH (1-29) exhibits a systemic plasma half-life of less than 12 minutes in rodent models due to rapid cleavage at the N-terminal Ala2 position. The structural substitution of D-Ala2 in CJC-1295 (No DAC) extends half-life to approximately 30 minutes in vivo, permitting sustained GHRH receptor occupancy while avoiding the hyper-extended half-life associated with the Drug Affinity Complex (DAC) modification. Preclinical studies suggest that this mid-range half-life preserves natural physiological GH pulsatility without inducing receptor desensitization or continuous somatotroph fatigue.

Molecular Structure and Pharmacokinetics: SS-31 (Elamipretide)

SS-31 (Szeto-Schiller 31 or Elamipretide) is a novel aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. Designed specifically to cross the outer mitochondrial membrane without relying on potential-dependent transport mechanisms, SS-31 targets electron transport chain complexes directly.

The molecular architectural advantage of SS-31 lies in its structural motif featuring alternating basic and aromatic amino acid residues. This allows the molecule to concentrate over 1,000-fold within the inner mitochondrial membrane (IMM). In vitro data indicate that SS-31 electrostatic interactions are specifically mediated by cardiolipin, an essential phospholipid exclusive to the IMM. Because it bypasses traditional cell-surface receptor binding pathways, SS-31 displays linear pharmacokinetic distribution in cellular assays, with intracellular retention observed for several hours post-incubation.

Signal Transduction Pathways: GHRH vs. Cardiolipin Interaction

The primary signal transduction cascade initiated by CJC-1295 (No DAC) depends on binding to the GHRH receptor, a classical G-protein coupled receptor (GPCR) localized on anterior pituitary somatotrophs. Activation of GHRHR stimulates membrane-bound adenylyl cyclase, driving an intracellular accumulation of cyclic adenosine monophosphate (cAMP). This activates protein kinase A (PKA), causing an influx of extracellular calcium ions through voltage-gated channels and triggering the exocytosis of pre-stored growth hormone vesicles.

In contrast, SS-31 operates entirely independent of GPCR signaling pathways. The tetrapeptide inserts into the hydrophobic matrix of cardiolipin, preventing the peroxidation of this critical phospholipid by cytochrome c oxidase. By maintaining cardiolipin structural integrity, SS-31 stabilizes cristae architecture, optimizes electron transfer through Complexes I–IV, reduces electron leakage, and minimizes intracellular reactive oxygen species (ROS) formation. In models of cellular stress, this mechanism prevents the opening of the mitochondrial permeability transition pore (mPTP) and inhibits pro-apoptotic signal cascades.

Preclinical Literature: Endocrine Pulsatility and Tissue Repair

Preclinical studies investigating CJC-1295 (No DAC) predominantly focus on endocrine response and systemic protein synthesis parameters. In rodent assays, administration of CJC-1295 (No DAC) induces a rapid, dose-dependent rise in plasma growth hormone concentration, followed by secondary increases in systemic Insulin-Like Growth Factor 1 (IGF-1) synthesized in hepatic tissue.

In vitro models evaluating skeletal muscle satellite cells show that elevated IGF-1 signaling secondary to GHRH activation upregulates mammalian target of rapamycin (mTOR) pathways, promoting nitrogen retention and accelerating protein translation. Furthermore, animal models exploring connective tissue turnover indicate that GHRH-mediated GH release stimulates collagen cross-linking in tendon, ligament, and cutaneous tissues, making CJC-1295 (No DAC) a valuable reagent for wound healing and tissue repair research.

Preclinical Literature: Mitochondrial Energetics and ROS Mitigation

Scientific literature surrounding SS-31 focuses heavily on acute organ injury, neurodegeneration, and metabolic dysregulation. In vitro assays using isolated mitochondria demonstrate that SS-31 treatment restores ATP synthesis capacity under conditions of hypoxia and nutrient deprivation. By binding cardiolipin, the compound preserves ATP synthase activity and prevents the structural degradation of electron transport chain supercomplexes.

In animal models of cardiac ischemia-reperfusion injury, SS-31 administration significantly decreased microvascular damage, reduced myocardial infarct size, and suppressed systemic markers of oxidative stress. Similarly, neurobiology research utilizing rodent models of neurodegenerative decline demonstrates that SS-31 crosses the blood-brain barrier to attenuate microglial activation, reduce mitochondrial fragmentation in hippocampal neurons, and maintain cognitive processing markers under neurotoxic exposure.

Study Design Considerations: Selecting the Optimal Reagent

Determining whether to incorporate CJC-1295 (No DAC) or SS-31 into a research protocol depends entirely on the biological primary endpoints of the study:

1. **Select CJC-1295 (No DAC)** if the investigation centers on endocrine axes, somatotroph responsiveness, systemic IGF-1 induction, muscle protein accretion, or bone density alterations secondary to growth factor secretion. 2. **Select SS-31** if the protocol investigates organelle-specific failure, cardiolipin oxidation, electron transport chain kinetics, ischemia-reperfusion protocols, or oxidative stress reduction in cardiac, renal, or neuronal cell lines. 3. **Dual-Vector Protocols**: In advanced cellular stress research, investigators sometimes deploy both compounds in parallel or combined designs to analyze whether mitochondrial bioenergetic optimization (SS-31) synergizes with growth factor-driven anabolic repair (CJC-1295 No DAC) during post-injury recovery phases.

All experimental designs should consult our comprehensive research hub for technical whitepapers and mechanistic breakdowns across peptide classes.

Comparative Analysis: Growth Hormone Secretagogues and Class Variants

To contextualize CJC-1295 (No DAC) within its broader pharmacological class, researchers often compare it against other growth hormone secretagogues. While GHRH analogs like Sermorelin share similar short-acting properties, CJC-1295 (No DAC) offers superior enzymatic stability due to its four-amino-acid modification. When compared to ghrelin receptor agonists such as Ipamorelin or GHRP-6, CJC-1295 operates through a completely distinct receptor cascade (GHRHR vs. GHSR-1a). Dual-activation protocols combining a GHRH analog with a GHRP are widely documented in literature to demonstrate synergism at the pituitary level.

On the other hand, SS-31 occupies a rare position in mitochondriotropic research, sharing functional overlap primarily with compounds involved in mitochondrial targeting research rather than traditional endocrine modulators.

Reconstitution, Handling, and Storage Protocols

Both CJC-1295 (No DAC) and SS-31 are supplied as highly purified, lyophilized cakes to ensure chemical stability during transport and storage. Upon receipt, lyophilized vials must be kept at -20°C for short-term preservation or -80°C for long-term storage.

For laboratory reconstitution, researchers should utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline under a laminar flow hood. Gently direct the solvent down the inner glass wall of the vial to avoid agitating the peptide matrix, allowing the powder to dissolve without high-speed vortexing.

To calculate exact reconstitution volumes and final molar concentration per milliliter, researchers should utilize our interactive reconstitution calculator. Once reconstituted, liquid solutions should be aliquoted into single-use microcentrifuge tubes to eliminate freeze-thaw cycles and maintained at 2°C to 8°C. Reconstituted solutions should generally be utilized within 14 to 28 days depending on the pH and buffer environment.

Quality Assurance, Analytical Verification, and Sourcing

Reproducibility in preclinical literature demands strict reagent quality standards. Variations in peptide purity, residual trifluoroacetic acid (TFA) content, or endotoxin contamination can confound experimental outcomes and introduce unintended cellular toxicity.

PX1 Research manufactures all research compounds within USA-based, ISO 17025-certified and cGMP-compliant facilities. Every production batch undergoes rigorous analytical testing, including high-performance liquid chromatography (HPLC) to verify purity (>98%) and mass spectrometry (MS) to confirm exact molecular identity. Furthermore, routine chromogenic LAL assays ensure bacterial endotoxin levels remain below strict laboratory safety thresholds.

Principal investigators and procurement specialists can access batch-specific Certificates of Analysis directly through our portal prior to placing orders. Institutional teams setting up bulk testing schedules can register for bulk lab ordering accounts to secure standardized multi-lot quantities with matched purity profiles.